Your browser doesn't support javascript.
loading
A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced On-Target, Off-Tumor Activation.
Di Roberto, Raphaël B; Castellanos-Rueda, Rocío; Frey, Samara; Egli, David; Vazquez-Lombardi, Rodrigo; Kapetanovic, Edo; Kucharczyk, Jakub; Reddy, Sai T.
Afiliación
  • Di Roberto RB; Department of Biosystems Science and Engineering, ETH Zürich, 4058 Basel, Switzerland.
  • Castellanos-Rueda R; Department of Biosystems Science and Engineering, ETH Zürich, 4058 Basel, Switzerland.
  • Frey S; Department of Biosystems Science and Engineering, ETH Zürich, 4058 Basel, Switzerland.
  • Egli D; Department of Biosystems Science and Engineering, ETH Zürich, 4058 Basel, Switzerland.
  • Vazquez-Lombardi R; Department of Biosystems Science and Engineering, ETH Zürich, 4058 Basel, Switzerland.
  • Kapetanovic E; Department of Biosystems Science and Engineering, ETH Zürich, 4058 Basel, Switzerland.
  • Kucharczyk J; Department of Biosystems Science and Engineering, ETH Zürich, 4058 Basel, Switzerland.
  • Reddy ST; Department of Biosystems Science and Engineering, ETH Zürich, 4058 Basel, Switzerland. Electronic address: sai.reddy@ethz.ch.
Mol Ther ; 28(12): 2564-2576, 2020 12 02.
Article en En | MEDLINE | ID: mdl-32827460
ABSTRACT
In recent years, chimeric antigen receptor (CAR) T cell cancer immunotherapies have advanced substantially in the clinic. However, challenges related to safety persist; one major concern occurs when CARs trigger a response to antigen present on healthy cells (on-target, off-tumor response). A strategy to ameliorate this relies on the complex relationship between receptor affinity and signaling, such that one can engineer a CAR that is only activated by tumor cells expressing high antigen levels. Here, we developed a CARcell display platform with stable genomic expression and rapid functional screening based on interleukin-2 signaling. Starting with a CAR with high affinity toward its target antigen, we combined CRISPR-Cas9 genome editing and deep mutational scanning to generate a library of antigen-binding domain variants. This library was subjected to multiple rounds of selection based on either antigen binding or cell signaling. Deep sequencing of the resulting libraries and a comparative analysis revealed the enrichment and depletion of specific variants from which we selected CARs that were selectively activated by tumor cells based on antigen expression levels. Our platform demonstrates how directed evolution based on functional screening and deep sequencing-guided selection can be combined to enhance the selectivity and safety of CARs.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias de la Mama / Inmunoterapia Adoptiva / Receptores de Antígenos de Linfocitos T alfa-beta / Receptor ErbB-2 / Ingeniería Celular / Receptores Quiméricos de Antígenos / Antígenos de Neoplasias Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Animals / Female / Humans Idioma: En Revista: Mol Ther Asunto de la revista: BIOLOGIA MOLECULAR / TERAPEUTICA Año: 2020 Tipo del documento: Article País de afiliación: Suiza

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias de la Mama / Inmunoterapia Adoptiva / Receptores de Antígenos de Linfocitos T alfa-beta / Receptor ErbB-2 / Ingeniería Celular / Receptores Quiméricos de Antígenos / Antígenos de Neoplasias Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Animals / Female / Humans Idioma: En Revista: Mol Ther Asunto de la revista: BIOLOGIA MOLECULAR / TERAPEUTICA Año: 2020 Tipo del documento: Article País de afiliación: Suiza